Systane® lubricant eye drops in the management of ocular dryness

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 783-790

  Benelli, Umberto ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Dimyristoylphosphatidylglycerol; Dry eye; Hydroxypropyl guar; Meibomian gland dysfunction; Systane balance; Systane ultra

Indexed keywords

AGENTS ACTING ON THE EYE; ARTIFICIAL TEAR; CYCLOSPORIN; EYE DROPS; SYSTANE; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DRY EYE; EYE BURNING; EYE IRRITATION; HUMAN; REVIEW; TREATMENT OUTCOME;

EID: 79959859707     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S13773     Document Type: Review

References (44)

1. International Dry Eye WorkShop. The definition and classification of dry eye disease: Report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2): 75-92.
2. Perry HD. Dry eye disease: Pathophysiology, classification, and diagnosis. Am J Manag Care. 2008;14(3 Suppl):S79-S87.
3. Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14 (3 Suppl):S88-S101.
4. Gayton JL. Etiology, prevalence, and treatment of dry eye disease. Clin Ophthalmol. 2009;3:405-412.
5. Foulks GN. Treatment of dry eye disease by the non-ophthalmologist. Rheum Dis Clin North Am. 2008;34(4):987-1000.
6. International Dry Eye WorkShop. The epidemiology of dry eye disease: Report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):93-107.
7. Gifford P, Evans BJ, Morris J. A clinical evaluation of Systane. Cont Lens Anterior Eye. 2006;29(1):31-40.
8. Rosenfeld SI. Evaluation and management of post-LASIK dry eye syndrome. Int Ophthalmol Clin. 2010;50(3):191-199.
9. Friedman NJ. Impact of dry eye disease and treatment on quality of life. Curr Opin Ophthalmol. 2010;21(4):310-316.
10. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S102-S106.
11. Foulks GN. The correlation between the tear film lipid layer and dry eye disease. Surv Ophthalmol. 2007;52(4):369-374.
12. Foulks GN, Borchman D. Meibomian gland dysfunction: The past, present, and future. Eye Contact Lens. 2010;36(5):249-253.
13. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf. 2004;2(2):149-165.
14. Bron AJ, Tiffany JM, Gouveia SM, Yokoi N, Voon LW. Functional aspects of the tear film lipid layer. Exp Eye Res. 2004;78(3): 347-360.
15. Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci. 1997;74(1):8-13.
16. Blackie CA, Solomon JD, Scaffidi RC, Greiner JV, Lemp MA, Korb DR. The relationship between dry eye symptoms and lipid layer thickness. Cornea. 2009;28(7):789-794.
17. Lemp MA, Foulks GN, Devgan U, Trattler WB, Nichols KK. The therapeutic role of lipids: Managing ocular surface disease. Refractive Eyecare for Ophthalmologists. 2005;9(Suppl):3-15.
18. Dry Eye WorkShop. Management and therapy of dry eye disease: Report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007;5(2):163-178.
19. Christensen MT, Cohen S, Rinehart J, et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res. 2004;28(1):55-62.
20. Springs CL. Novel hydroxypropyl-guar gellable lubricant eye drops for treatment of dry eye. Adv Ther. 2010;27(10):681-690.
21. Foulks GN. Clinical evaluation of the efficacy of PEG/PG lubricant eye drops with gelling agent (HP-Guar) for the relief of the signs and symptoms of dry eye disease: A review. Drugs Today (Barc).2007;43(12):887-896.
22. Springs C. Novel ocular lubricant containing an intelligent delivery system: Details of its mechanism of action. Dev Ophthalmol. 2010;45: 139-147.
23. Christensen MT. Corneal staining reductions observed after treatment with Systane® Lubricant Eye Drops. Adv Ther. 2008;25(11):1191-1199.
24. SYSTANE® lubricant eye drops. Available at: http://www.systane.com. Accessed March 14, 2011.
25. Ubels JL, Clousing DP, Van Haitsma TA, et al. Pre-clinical investigation of the efficacy of an artificial tear solution containing hydroxypropylguar as a gelling agent. Curr Eye Res. 2004;28(6):437-444.
26. Tripathi BJ, Tripathi RC, Kolli SP. Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res. 1992;9(3-4): 361-375.
27. Meyer AE, Baier RE, Chen H, Chowhan M. Differential tissue-on-tissue lubrication by ophthalmic formulations. J Biomed Mater Res B Appl Biomater. 2007;82(1):74-88.
28. Hartstein I, Khwarg S, Przydryga J. An open-label evaluation of HPguar gellable lubricant eye drops for the improvement of dry eye signs and symptoms in a moderate dry eye adult population. Curr Med Res Opin. 2005;21(2):255-260.
29. Rolando M, Autori S, Badino F, Barabino S. Protecting the ocular surface and improving the quality of life of dry eye patients: A study of the efficacy of an HP-guar containing ocular lubricant in a population of dry eye patients. J Ocul Pharmacol Ther. 2009;25(3):271-278.
30. Ousler GW, Michaelson C, Christensen MT. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea. 2007;26(8):949-952.
31. Benelli U, Nardi M, Posarelli C, Albert TG. Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness. Cont Lens Anterior Eye. 2010;33(2):61-67.
32. Paugh JR, Nguyen AL, Huang P, Hwang JS. Retention and retention of effect of topical formulations in dry eye subjects. Optom Vis Sci.2008;85(9):873-879.
33. Sanchez MA, Arriola-Villalobos P, Torralbo-Jimenez P, et al. The effect of preservative-free HP-Guar on dry eye after phacoemulsification: A flow cytometric study. Eye (Lond). 2010;24(8):1331-1337.
34. Versura P, Profazio V, Campos EC. One month use of Systane improves ocular surface parameters in subjects with moderate symptoms of ocular dryness. Clin Ophthalmol. 2008;2(3):629-635.
35. Durrie D, Stahl J. A randomized clinical evaluation of the safety of Systane lubricant eye drops for the relief of dry eye symptoms following LASIK refractive surgery. Clin Ophthalmol. 2008;2(4):973-979.
36. Ousler GW, Hagberg KW, Schindelar M, Welch D, Abelson MB. The Ocular Protection Index. Cornea. 2008;27(5):509-513.
37. Sall KN, Cohen SM, Christensen MT, Stein JM. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006;32(1):21-26.
38. Kading D. A two-week clinical evaluation of the safety of Systane Ultra in contact lens-wearing patients. Clin Ophthalmol. 2010;4:27-32.
39. Davitt WF, Bloomenstein M, Christensen M, Martin AE. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation. J Ocul Pharmacol Ther. 2010;26(4):347-353.
40. Systane® Ultra lubricant eye drops. Available at: http://www.systane.com. Accessed March 14, 2011.
41. Systane® Balance lubricant eye drops. Available at: http://www.systane.com. Accessed March 14, 2011.
42. Ketelson HA, Davis J, Meadows D. Characterization of an anionic lipid stabilized ocular emulsion containing HP-guar. Invest Ophthalmol Vis Sci. 2010;43:Abstract D892.
43. Korb DR, Blackie CA, Meadows D, Christensen MT, Tudor MR. Evaluation of extended tear stability by two emulsion based artificial tears. In: Proceedings of the 6th International Conference on the Tear Film and Ocular Surface: Basic Science and Clinical Relevance Tear Film and Ocular Surface Society meeting, Florence, Italy, September 22-25, 2010.
44. Foulks G, Sindt C, Griffin J. Efficacy evaluation of a novel emulsion based, anionic phospholipid containing artificial tear in meibomian gland dysfunction (MGD) subjects. In: Proceedings of the 6th International Conference on the Tear Film and Ocular Surface: Basic Science and Clinical Relevance Tear Film and Ocular Surface Society meeting, Florence, Italy, September 22-25, 2010.